Pharmacoepidemiology and Drug SafetyVolume 17, Issue 8 p. 782-786 Commentary The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment† Robert M. Califf MD, Corresponding Author Robert M. Califf MD [email protected] Duke Translational Medicine Institute, Durham, NC, USAVice Chancellor for Clinical Research; Director, Duke Translational Medicine Institute, Duke University Medical Center, 2400 Pratt Street, Box 17969, Durham, NC 27715, USA.Search for more papers by this authorJudith M. Kramer MD, MS, Judith M. Kramer MD, MS Duke Translational Medicine Institute, Durham, NC, USASearch for more papers by this author Robert M. Califf MD, Corresponding Author Robert M. Califf MD [email protected] Duke Translational Medicine Institute, Durham, NC, USAVice Chancellor for Clinical Research; Director, Duke Translational Medicine Institute, Duke University Medical Center, 2400 Pratt Street, Box 17969, Durham, NC 27715, USA.Search for more papers by this authorJudith M. Kramer MD, MS, Judith M. Kramer MD, MS Duke Translational Medicine Institute, Durham, NC, USASearch for more papers by this author First published: 24 July 2008 https://doi.org/10.1002/pds.1617Citations: 5 † Dr Califf receives significant (≥$10 000) grant support from NICHD 1UL1RR024128-01. Dr Califf receives consulting income from the following: nonsignificant (<$10 000): Avalere Health, Biogen Idec, Brandeis University, Bristol Meyers-Squibb/Sanofi, Five Prime, Sanofi-Aventis, Scios Pharma, Vertex; significant: Bayer, Heart.org (Conceptis), Kowa Research Institute, Merck, Nitrox LLC, Novartis, Schering Plough. All consulting income is donated to non-profit organizations, with the majority being designated for the Duke Clinical Research Institute's clinical fellowship fund. Dr Califf receives salary support from the following: Merck, Novartis Pharmaceuticals, Schering Plough, Scios Pharma (all payments are made to Duke University). Dr Califf's educational activities result in revenue from the following for Duke University: nonsignificant: Merck, Sanofi-Aventis, Schering-Plough; significant: Heart.org/Conceptis, Kowa Research Institute, Novartis Pharmaceuticals, Scios Pharma. Dr Califf holds equity in excess of $10 000 in Nitrox LLC. Dr Kramer's salary is partially supported by a grant from Pfizer. Dr Kramer has received nonsignificant (<$10 000) consulting income from Icagen and Lilly, and receives significant (≥$10 000) consulting income from Sanofi-Pasteur. Dr Kramer is a member of the U.S. Food and Drug Administration's Drug Safety and Risk Management Advisory Committee. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume17, Issue8August 2008Pages 782-786 RelatedInformation